| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Nautilus Biotechnology, Inc.
13D/A
NAUT · 63909J108
|
4.9% |
9/11/2026
Event 9/9/2026
|
||||
| AH Bio Fund II, L.P. | 4.5% | |||||
| AH Equity Partners Bio II, L.L.C. | 4.5% | |||||
| Andreessen Horowitz LSV Fund II, L.P. | 0.4% | |||||
| AH Equity Partners LSV II, L.L.C. | 0.4% | |||||
| Marc L. Andreessen | 4.9% | |||||
| Benjamin A. Horowitz | 4.9% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.